Cargando…
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study
Proliferating Cell Nuclear Antigen (PCNA) is a highly conserved protein essential for DNA replication, repair and scaffold functions in the cytosol. Specific inhibition of PCNA in cancer cells is an attractive anti-cancer strategy. ATX-101 is a first-in-class drug targeting PCNA, primarily in cellul...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918429/ https://www.ncbi.nlm.nih.gov/pubmed/36564469 http://dx.doi.org/10.1038/s41388-022-02582-6 |
_version_ | 1784886605683621888 |
---|---|
author | Lemech, Charlotte Rose Kichenadasse, Ganessan Marschner, Jens-Peter Alevizopoulos, Konstantinos Otterlei, Marit Millward, Michael |
author_facet | Lemech, Charlotte Rose Kichenadasse, Ganessan Marschner, Jens-Peter Alevizopoulos, Konstantinos Otterlei, Marit Millward, Michael |
author_sort | Lemech, Charlotte Rose |
collection | PubMed |
description | Proliferating Cell Nuclear Antigen (PCNA) is a highly conserved protein essential for DNA replication, repair and scaffold functions in the cytosol. Specific inhibition of PCNA in cancer cells is an attractive anti-cancer strategy. ATX-101 is a first-in-class drug targeting PCNA, primarily in cellular stress regulation. Multiple in vivo and in vitro investigations demonstrated anti-cancer activity of ATX-101 in many tumor types and a potentiating effect on the activity of anti-cancer therapies. Healthy cells were less affected. Based on preclinical data, a clinical phase 1 study was initiated. Twenty-five patients with progressive, late-stage solid tumors were treated with weekly ATX-101 infusions at four dose levels (20, 30, 45, 60 mg/m(2)). ATX-101 showed a favorable safety profile supporting that vital cellular functions are not compromised in healthy cells. Mild and moderate infusion-related reactions were observed in 64% of patients. ATX-101 was quickly cleared from blood with elimination half-lives of less than 30 min at all dose levels, probably due to both, a quick cell penetration and peptide digestion in serum, as demonstrated in vivo. No tumor responses were observed but stable disease was seen in 70% of the efficacy population (n = 20). Further studies have been initiated to provide evidence of efficacy. Trial registration numbers: ANZCTR 375262 and ANZCTR 375319. |
format | Online Article Text |
id | pubmed-9918429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-99184292023-02-12 ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study Lemech, Charlotte Rose Kichenadasse, Ganessan Marschner, Jens-Peter Alevizopoulos, Konstantinos Otterlei, Marit Millward, Michael Oncogene Brief Communication Proliferating Cell Nuclear Antigen (PCNA) is a highly conserved protein essential for DNA replication, repair and scaffold functions in the cytosol. Specific inhibition of PCNA in cancer cells is an attractive anti-cancer strategy. ATX-101 is a first-in-class drug targeting PCNA, primarily in cellular stress regulation. Multiple in vivo and in vitro investigations demonstrated anti-cancer activity of ATX-101 in many tumor types and a potentiating effect on the activity of anti-cancer therapies. Healthy cells were less affected. Based on preclinical data, a clinical phase 1 study was initiated. Twenty-five patients with progressive, late-stage solid tumors were treated with weekly ATX-101 infusions at four dose levels (20, 30, 45, 60 mg/m(2)). ATX-101 showed a favorable safety profile supporting that vital cellular functions are not compromised in healthy cells. Mild and moderate infusion-related reactions were observed in 64% of patients. ATX-101 was quickly cleared from blood with elimination half-lives of less than 30 min at all dose levels, probably due to both, a quick cell penetration and peptide digestion in serum, as demonstrated in vivo. No tumor responses were observed but stable disease was seen in 70% of the efficacy population (n = 20). Further studies have been initiated to provide evidence of efficacy. Trial registration numbers: ANZCTR 375262 and ANZCTR 375319. Nature Publishing Group UK 2022-12-23 2023 /pmc/articles/PMC9918429/ /pubmed/36564469 http://dx.doi.org/10.1038/s41388-022-02582-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Brief Communication Lemech, Charlotte Rose Kichenadasse, Ganessan Marschner, Jens-Peter Alevizopoulos, Konstantinos Otterlei, Marit Millward, Michael ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study |
title | ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study |
title_full | ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study |
title_fullStr | ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study |
title_full_unstemmed | ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study |
title_short | ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study |
title_sort | atx-101, a cell-penetrating protein targeting pcna, can be safely administered as intravenous infusion in patients and shows clinical activity in a phase 1 study |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918429/ https://www.ncbi.nlm.nih.gov/pubmed/36564469 http://dx.doi.org/10.1038/s41388-022-02582-6 |
work_keys_str_mv | AT lemechcharlotterose atx101acellpenetratingproteintargetingpcnacanbesafelyadministeredasintravenousinfusioninpatientsandshowsclinicalactivityinaphase1study AT kichenadasseganessan atx101acellpenetratingproteintargetingpcnacanbesafelyadministeredasintravenousinfusioninpatientsandshowsclinicalactivityinaphase1study AT marschnerjenspeter atx101acellpenetratingproteintargetingpcnacanbesafelyadministeredasintravenousinfusioninpatientsandshowsclinicalactivityinaphase1study AT alevizopouloskonstantinos atx101acellpenetratingproteintargetingpcnacanbesafelyadministeredasintravenousinfusioninpatientsandshowsclinicalactivityinaphase1study AT otterleimarit atx101acellpenetratingproteintargetingpcnacanbesafelyadministeredasintravenousinfusioninpatientsandshowsclinicalactivityinaphase1study AT millwardmichael atx101acellpenetratingproteintargetingpcnacanbesafelyadministeredasintravenousinfusioninpatientsandshowsclinicalactivityinaphase1study |